XBIOW
Income statement / Annual
Last year (2023), Xenetic Biosciences, Inc.'s total revenue was $2.54 M,
an increase of 48.80% from the previous year.
In 2023, Xenetic Biosciences, Inc.'s net income was -$4.13 M.
See Xenetic Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$2.54 M
|
$1.71 M
|
$1.16 M
|
$436,942.00
|
$17,066.00
|
$0.00
|
$7.59 M
|
$3.00 M
|
$0.00
|
$0.00
|
Cost of Revenue |
$0.00 |
$27,043.00 |
$35,482.00 |
$0.00 |
$0.00 |
$15,827.00 |
$156,119.00 |
$36,449.00 |
$56,115.00 |
$0.00 |
Gross Profit |
$2.54 M |
$1.68 M |
$1.13 M |
$436,942.00 |
$17,066.00 |
-$15,827.00 |
$7.43 M |
$2.96 M |
-$56,115.00 |
$0.00 |
Gross Profit Ratio |
1 |
0.98 |
0.97 |
1 |
1 |
0 |
0.98 |
0.99 |
0 |
0 |
Research and Development
Expenses |
$3.49 M
|
$4.77 M
|
$3.16 M
|
$1.73 M
|
$4.89 M
|
$2.88 M
|
$4.06 M
|
$43.74 M
|
$3.43 M
|
$6.32 M
|
General & Administrative
Expenses |
$3.56 M
|
$3.65 M
|
$3.74 M
|
$3.40 M
|
$4.73 M
|
$4.39 M
|
$6.94 M
|
$6.69 M
|
$6.39 M
|
$6.60 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$3.56 M
|
$3.65 M
|
$3.74 M
|
$3.40 M
|
$4.73 M
|
$4.39 M
|
$6.94 M
|
$6.69 M
|
$6.39 M
|
$6.60 M
|
Other Expenses |
$0.00 |
-$1,597.00 |
$1,119.00 |
-$492.00 |
$3,315.00 |
-$24,640.00 |
-$41,096.00 |
$0.00 |
$0.00 |
$0.00 |
Operating Expenses |
$7.06 M |
$8.42 M |
$6.91 M |
$5.13 M |
$9.62 M |
$7.28 M |
$11.00 M |
$50.43 M |
$9.82 M |
$12.92 M |
Cost And Expenses |
$7.06 M |
$8.42 M |
$6.91 M |
$5.13 M |
$9.62 M |
$7.28 M |
$11.15 M |
$50.43 M |
$9.82 M |
$12.92 M |
Interest Income |
$355,757.00 |
$167,152.00 |
$100,467.00 |
$126,171.00 |
$216,978.00 |
$0.00 |
$16,544.00 |
$32.00 |
$1,694.00 |
$18,959.00 |
Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$24,131.00 |
$1,818.00 |
$729,572.00 |
$266,999.00 |
$4,706.00 |
Depreciation &
Amortization |
$0.00
|
$27,043.00
|
$35,482.00
|
$28,837.00
|
$27,487.00
|
$15,827.00
|
$23,784.00
|
$36,449.00
|
$56,115.00
|
$88,689.00
|
EBITDA |
-$4.52 M
|
-$6.72 M
|
-$5.71 M
|
-$4.69 M
|
-$9.58 M
|
-$7.26 M
|
-$3.57 M
|
-$53.44 M
|
-$9.77 M
|
-$14.21 M
|
EBITDA Ratio |
-1.78 |
-3.92 |
-4.92 |
10.48 |
-368.72 |
0 |
-0.47 |
-15.8 |
0 |
0 |
Operating Income Ratio
|
-1.78
|
-3.94
|
-4.95
|
10.41
|
-755.12
|
0
|
-0.47
|
-15.81
|
0
|
0
|
Total Other
Income/Expenses Net |
$381,137.00
|
$165,555.00
|
$101,586.00
|
$125,679.00
|
$111,804.00
|
-$24,131.00
|
-$26,370.00
|
-$6.78 M
|
-$2.69 M
|
-$1.38 M
|
Income Before Tax |
-$4.13 M |
-$6.55 M |
-$5.65 M |
-$13.81 M |
-$12.78 M |
-$7.30 M |
-$3.60 M |
-$54.21 M |
-$12.51 M |
-$14.31 M |
Income Before Tax Ratio
|
-1.63
|
-3.84
|
-4.86
|
-31.61
|
-748.57
|
0
|
-0.47
|
-18.07
|
0
|
0
|
Income Tax Expense |
$0.00 |
-$165,555.00 |
-$100,467.00 |
-$2.92 M |
$3.17 M |
$24,131.00 |
$26,370.00 |
$6.05 M |
$2.42 M |
$1.40 M |
Net Income |
-$4.13 M |
-$6.39 M |
-$5.54 M |
-$10.89 M |
-$15.95 M |
-$7.30 M |
-$3.60 M |
-$54.21 M |
-$12.51 M |
-$14.31 M |
Net Income Ratio |
-1.63 |
-3.74 |
-4.78 |
-24.93 |
-934.6 |
0 |
-0.47 |
-18.07 |
0 |
0 |
EPS |
-2.71 |
-4.49 |
-5.39 |
-17.04 |
-55.92 |
-96.58 |
-49.78 |
-875.41 |
-355.34 |
-416.91 |
EPS Diluted |
-2.71 |
-4.49 |
-5.39 |
-17.04 |
-55.92 |
-96.57 |
-49.78 |
-875.41 |
-355.34 |
-416.91 |
Weighted Average Shares
Out |
$1.53 M
|
$1.42 M
|
$1.03 M
|
$639,238.00
|
$285,246.00
|
$75,590.00
|
$72,214.00
|
$61,921.00
|
$35,199.00
|
$34,317.00
|
Weighted Average Shares
Out Diluted |
$1.53 M
|
$1.42 M
|
$1.03 M
|
$639,238.00
|
$285,246.00
|
$75,601.00
|
$72,214.00
|
$61,921.00
|
$35,199.00
|
$34,317.00
|
Link |
|
|
|
|
|
|
|
|
|
|